To further identify the function of miR-182 and explore its potential application in AML clinical treatment, MLL-AF9+ AML cells were transduced with LVX-puro-mmu-miR-182 (182OE) or negative vector (182NC). Here, MLLT3 is linked to acute myeloid leukemia.